UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Journal of the American Academy of Dermatology, 2017-03, Vol.76 (3), p.405-417

2017

Volltextzugriff (PDF)

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

The Lancet (British edition), 2017-07, Vol.390 (10091), p.276-288

2017

Volltextzugriff (PDF)

Hidradenitis suppurativa: Epidemiology and scope of the problem

Journal of the American Academy of Dermatology, 2015-11, Vol.73 (5), p.S4-S7

2015

Volltextzugriff (PDF)

Systemic associations of hidradenitis suppurativa

Journal of the American Academy of Dermatology, 2015-11, Vol.73 (5), p.S27-S35

2015

Volltextzugriff (PDF)

Psoriasis Epidemiology: The Interplay of Genes and the Environment

Journal of investigative dermatology, 2013-02, Vol.133 (2), p.287-289

2013

Volltextzugriff (PDF)

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

The New England journal of medicine, 2016-08, Vol.375 (5), p.422-434

2016

Volltextzugriff (PDF)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

The Lancet (British edition), 2008-05, Vol.371 (9625), p.1665-1674

2008

Volltextzugriff (PDF)

Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States

Journal of the American Academy of Dermatology, 2016-01, Vol.74 (1), p.190-192

2016

Volltextzugriff (PDF)

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Journal of the American Academy of Dermatology, 2008, Vol.58 (1), p.106-115

2008

Volltextzugriff (PDF)

Itch intensity in moderate-to-severe plaque psoriasis versus atopic dermatitis: A meta-analysis

Journal of the American Academy of Dermatology, 2017-06, Vol.76 (6), p.1198-1200.e1

2017

Volltextzugriff (PDF)

Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy

Journal of the American Academy of Dermatology, 2020-10, Vol.83 (4), p.1215-1218

2020

Volltextzugriff (PDF)

Risks of developing psychiatric disorders in pediatric patients with psoriasis

Journal of the American Academy of Dermatology, 2012-10, Vol.67 (4), p.651-657.e2

2012

Volltextzugriff (PDF)

Transcriptomic analysis of human skin wound healing and rejuvenation following ablative fractional laser treatment

PloS one, 2021-11, Vol.16 (11), p.e0260095-e0260095

2021

Volltextzugriff (PDF)

National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening

Journal of the American Academy of Dermatology, 2008-06, Vol.58 (6), p.1031-1042

2008

Volltextzugriff (PDF)

Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis

Journal of the American Academy of Dermatology, 2006-10, Vol.55 (4), p.607-613

2006

Volltextzugriff (PDF)

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

Journal of the American Academy of Dermatology, 2010-09, Vol.63 (3), p.457-465

2010

Volltextzugriff (PDF)

Counterpoint: Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States

Journal of the American Academy of Dermatology, 2013-11, Vol.69 (5), p.818-819

2013

Volltextzugriff (PDF)

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])

Journal of the American Academy of Dermatology, 2016-05, Vol.74 (5), p.851-861.e4

2016

Volltextzugriff (PDF)

Gender Equity and Academic Dermatology: Are we giving the right advice?

Journal of the European Academy of Dermatology and Venereology, 2024-08, Vol.38 (8), p.1453-1454

Kimball, Alexa B.

2024

Volltextzugriff (PDF)

Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice

American journal of clinical dermatology, 2020-08, Vol.21 (4), p.579-590

2020

Volltextzugriff (PDF)

Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial

Dermatology and therapy, 2023-05, Vol.13 (5), p.1099-1111

2023

Volltextzugriff (PDF)

TNF-α inhibitors in the treatment of hidradenitis suppurativa

Therapeutic Advances in Chronic Disease, 2019, Vol.10, p.2040622319851640-2040622319851640

2019

Volltextzugriff (PDF)

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials

Journal of the American Academy of Dermatology, 2012-05, Vol.66 (5), p.742-751

2012

Volltextzugriff (PDF)

Development and initial psychometric evaluation of patient-reported outcome questionnaires to evaluate the symptoms and impact of hidradenitis suppurativa

The Journal of dermatological treatment, 2018-02, Vol.29 (2), p.152-164

2018

Volltextzugriff (PDF)

Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis

Journal of the American Academy of Dermatology, 2012-07, Vol.67 (1), p.76-85

2012

Volltextzugriff (PDF)

1 – 25 von 295

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(258)
Mit Volltextzugriff
(232)

Publikationsform

Sprache

Englisch
(294)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

Hidradenitis suppurativa: Epidemiology and scope of the problem

Systemic associations of hidradenitis suppurativa

Psoriasis Epidemiology: The Interplay of Genes and the Environment

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Itch intensity in moderate-to-severe plaque psoriasis versus atopic dermatitis: A meta-analysis

Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy

Risks of developing psychiatric disorders in pediatric patients with psoriasis

Transcriptomic analysis of human skin wound healing and rejuvenation following ablative fractional laser treatment

National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening

Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

Counterpoint: Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])

Gender Equity and Academic Dermatology: Are we giving the right advice?

Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice

Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial

TNF-α inhibitors in the treatment of hidradenitis suppurativa

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials

Development and initial psychometric evaluation of patient-reported outcome questionnaires to evaluate the symptoms and impact of hidradenitis suppurativa

Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis

Suchergebnisse filtern